Terms: = Prostate cancer AND PAX3, MGC120382, 5077, ENSG00000135903, CDHS, MGC120383, HUP2, P23760, WS1, MGC120384, MGC134778, MGC120381 AND Treatment
11 results:
1. pax3 silencing inhibits prostate cancer progression through the suppression of the TGF-β/Smad signaling axis.
Zeng K; Xie W; Huang J; Yang J; Deng K; Luo X
Cell Biol Int; 2020 Oct; 44(10):2131-2139. PubMed ID: 32672875
[TBL] [Abstract] [Full Text] [Related]
2. Early detection of the pax3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma.
Eguchi-Ishimae M; Tezuka M; Kokeguchi T; Nagai K; Moritani K; Yonezawa S; Tauchi H; Tokuda K; Ishida Y; Ishii E; Eguchi M
Genes Chromosomes Cancer; 2019 Aug; 58(8):521-529. PubMed ID: 30739374
[TBL] [Abstract] [Full Text] [Related]
3. UV-Radiation Response Proteins Reveal Undifferentiated Cutaneous Interfollicular Melanocytes with Hyperradiosensitivity to Differentiation at 0.05 Gy Radiotherapy Dose Fractions.
Fessé P; Qvarnström F; Nyman J; Hermansson I; Ahlgren J; Turesson I
Radiat Res; 2019 Jan; 191(1):93-106. PubMed ID: 30407899
[TBL] [Abstract] [Full Text] [Related]
4. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
5. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract] [Full Text] [Related]
6. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
[TBL] [Abstract] [Full Text] [Related]
7. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
Nanda A; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA; 2009 Aug; 302(8):866-73. PubMed ID: 19706860
[TBL] [Abstract] [Full Text] [Related]
8. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract] [Full Text] [Related]
9. Laparoscopic radical prostatectomy: preliminary result of Thailand series.
Nualyong C; Srinualnad S; Taweemonkongsap T; Amornvesukit T
J Med Assoc Thai; 2006 Sep; 89(9):1440-6. PubMed ID: 17100382
[TBL] [Abstract] [Full Text] [Related]
10. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
O'Sullivan JM; Norman AR; McCready VR; Flux G; Buffa FM; Johnson B; Coffey J; Cook G; Treleaven J; Horwich A; Huddart RA; Parker CC; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1055-61. PubMed ID: 16572306
[TBL] [Abstract] [Full Text] [Related]
11. Sequelae of radical prostatectomy.
Jønler M; Messing EM; Rhodes PR; Bruskewitz RC
Br J Urol; 1994 Sep; 74(3):352-8. PubMed ID: 7953267
[TBL] [Abstract] [Full Text] [Related]
